| Trade name(s) | ATG-Fresenius® S |
| Classification | IMMUNOGLOBULIN IMMUNE SUPPRESSANT |
| Indication(s) | Adjunct in the treatment and prevention of allograft rejection. |
| Presentation | 100mg in 5mL and 100mg in 10mL, vials. Also supplied with rabbit Ig challenge solution,
20mg in 2mL, vial. |
| Storage | Refrigerate - do not freeze. Protect from light. |
| Reconstitution | Not required. |
| Stability | Discard if a precipitate or cloudiness is present. |
| Compatible Fluid(s) NS† †Use within 12 hours of preparation. |
| Incompatible Fluid(s) |
| Incompatible Drug(s) Avoid mixing in solution with any other drugs. |
| Administration (Mode) IVI: INTERMITTENT INFUSION |
| Intravenous Concentration Intermittent Infusion: Dilute the required dose in 250 to 500mL of fluid. |
| Intravenous Rate Intermittent Infusion: Infuse over at least 4 hours. |
| Manner of Administration and Dosage Guide Adult : Prophylaxis: 2 to 5mg/kg/24 h for a duration of 9 to 14 days. Therapy: 3 to 5mg/kg/24 h for a duration of 14 days, commencing the day of first rejection. Skin testing (for allergy) prior to administration is recommended. |
| Adverse Effect(s) Anaphylactoid reactions (hypotension, sensation of chest tightness, fever, urticaria), serum sickness, thrombocytopenia, granulocytopenia |
| Precaution(s) Check for hypersensitivity to anti-human T-lymphocyte globulin (ATG) before administration. Do not use ATG in patients showing intolerance to rabbit protein in the allergy challenge test. Cease the infusion if any signs or symptoms of shock occur. Resuscitative equipment should be readily available during infusion. Monitor vital signs. |
| Additional Information Intracutaneous Test: Inject subcutaneously 0.1mL of the undiluted challenge solution (rabbit immunoglobulin) into the forearm. Marked erythema and/or oedema at the injection site within 15 minutes indicates intolerance. Sodium chloride 0.9% w/v is the control solution and should be administered concurrently into the respective contralateral site. If intolerance is suspected, or if the patient has received previous ATG therapy, then use a 1:100 dilution (with sodium chloride 0.9% w/v) of the challenge solution. Alternatively, the ATG-Fresenius® S solution 0.05mL (instead of 0.1mL as above) may be used instead of the test serum. Use the same methodology. Hdx: No data. Pdx: No data. Sodium: Negligible. Displacement: - ©1997 JBC Handbook™ 4th edition ISBN: 0 646 326 767 |